Additionally, Ubiquitin-specific peptidase 8 (USP8) inhibition markedly boosted and activated the CD8+ T cells through increasing the expression of PD-L1 in tumor cells and triggering the NF-κB pathway, thereby inhibiting tumor growth, improving the outcomes of anti-PD-L1 therapy (Xiong et al., 2022). This evidence concerns the gene CD8A and neoplasm.